T-Cure Bioscience Announces U.S. FDA Clearance of Investigator-Initiated Clinical Trial for KK-LC-1 TCR-T Against Multiple Solid Tumors

LOS ANGELES--(BUSINESS WIRE)--T-Cure Bioscience, Inc., a privately held company focused on developing autologous T cell receptor therapy (TCR-T) products for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate a Phase I clinical study...

Click to view original post